tofacitinib
Selected indexed studies
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. (N Engl J Med, 2017) [PMID:28467869]
- Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. (Ann Rheum Dis, 2021) [PMID:33906853]
- Tofacitinib experience in patients with enteropathic arthritis. (Immunotherapy, 2023) [PMID:37009645]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. (2017) pubmed
- Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. (2021) pubmed
- Tofacitinib experience in patients with enteropathic arthritis. (2023) pubmed
- Tofacitinib in paediatric dermatoses: a narrative review. (2022) pubmed
- Tofacitinib for the treatment of psoriasis and psoriatic arthritis. (2020) pubmed
- Tofacitinib for Acute Severe Ulcerative Colitis: A Systematic Review. (2023) pubmed
- Tofacitinib for the treatment of rheumatoid arthritis: an update. (2019) pubmed
- Tofacitinib in psoriatic arthritis. (2017) pubmed
- [Tofacitinib]. (2014) pubmed
- Tofacitinib-induced eosinophilia. (2023) pubmed